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Summary
OBJECTIVE: To evaluate the effect of IL-6 blockade using tocilizumab
in inducing remission of arterial large vessel vasculitides (LVV).
METHODS: Five consecutive patients with giant-cell arteritis (GCA) and
two with Takayasu’s arteritis (TA) were treated by tocilizumab infusions
(8 mg/kg). Tocilizumab was given every other week for the first month
and once monthly thereafter. Clinical symptoms of disease activity,
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level and
glucocorticoid (GC) dosage necessary to maintain remission were
prospectively assessed. MR angiography was performed to monitor local
inflammation.
RESULTS: Of the seven patients three were newly diagnosed and four
showed GC resistance, i.e. GC could not be lowered to less than 7.5 mg/
day. The mean follow-up time was 4.3 months (range 3–7 months). All
patients achieved a rapid and complete clinical response and
normalisation of the acute phase proteins. Remarkably, prednisone dosage
could be reduced within 12 weeks to a mean of 2.5 mg/day (range 0–10
mg/day). No relapse and no drug-related side effects were noted.
CONCLUSION: Collectively the data suggest that IL-6 blockade using
tocilizumab qualifies as a therapeutic option to induce rapid remission in
large vessel vasculitides.
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Introduction
Giant-cell arteritis (GCA) is an immune-mediated disease characterised by granulomatous infiltrates in the wall of
medium-size and large arteries including the aorta. It affects over-50-year-olds with an annual incidence varying between
6 and 27 cases per 100 000 persons worldwide [1]. Glucocorticoids (GCs) remain the treatment of choice. They suppress
signs and symptoms of inflammation and reduce the risk of vascular accidents such as blindness [2]. Takayasu’s arteritis
(TA) is a rare variant of GCA chiefly affecting young females. Ongoing inflammation causes severe vascular damage and
formation of stenoses and aneurysms, both of which may lead to fatal vascular accidents.
In both forms of large-vessel vasculitis relapses may occur when GC dosages are tapered, resulting in retreatment and
high cumulative dosages which are associated with substantial toxicity and morbidity [3]. Thus immunosuppressive drugs
such as methotrexate (MTX) and azathioprine (AZA), but also TNF-blocking agents, have been studied with a view to
controlling disease and economising GC. While MTX was shown to bestow some benefit [4, 5]¸ the data on AZA remain
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Figure 1
Abdominal magnetic resonance angiography
of GCA patient 3 using a 3 Tesla scanner
(first exam in the left column, right column
after therapy). The inflammatory tissue is
depicted as an irregular band with slightly
higher signal intensity on non-enhanced T1
weighted images (arrows). After intravenous
injection of paramagnetic contrast, this band
enhanced conspicuously. After therapy with
tocilizumab for three months, the extent of
the band decreased and signal intensity after
paramagnetic contrast was also considerably
lower.
controversial [6] and the TNF-blocking agents infliximab and etanercept were not successful in inducing and maintaining
disease remission [7, 8].
IL-6 plays an important role in the pathogenesis of GCA. IL-6 levels are elevated in active disease, correlate with the
acute phase response (CRP) and decline in response to GC therapy [9, 10]. Similarly to GCA, serum IL-6 levels have
been reported to be elevated in patients with TA and to correlate with disease activity [11]. Collectively, current evidence
indicates that IL-6 may be a good target molecule to induce remission in LVV. This hypothesis is supported by a recent
case report of a patient with TA showing improvement in clinical symptoms and laboratory signs in response to blockade
of IL-6 using the humanised anti-IL-6 receptor (IL-6R) antibody, tocilizumab (TCZ) [12].
Methods
Between December 2009 and July 2010 consecutive patients admitted to hospital for newly diagnosed or relapsing LVV
and without contraindications for TCZ were asked to accept treatment with TCZ. Clinical (constitutional, polymyalgia,
headache, claudication) and laboratory (elevated ESR, CRP) signs and symptoms of active vasculitis were assessed
initially and at each infusion of TCZ. Biopsies of temporal arteries were performed and contrast-enhanced MR
angiography (MRA) of the aorta was carried out before initiation of treatment and one and three months thereafter. Initial
biopsies were positive in 3 and negative in 2 GCA patients. All biopsy-negative GCA patients had MRA findings
characteristic for LVV. Granulomatous aortitis with giant cells was documented in one aortitis patient and typical MRA
findings were present in both patients with TA. Four of five GCA patients and both TA patients fulfilled the ACR
classification criteria [13, 14]. GC usage and adverse effects of TCZ were monitored.
Following detailed discussion all patients gave informed oral consent.
Results
Of the seven patients, three had histologically proven GCA in the biopsies
of the temporal artery, and one of them also showed active aortitis on
MRA. Two patients presented with aortitis as assessed by MRA but
without temporal arteritis, and two patients had established TA based on
clinical and MRA findings, one of them also having histologically proven
granulomatous vasculitis.
The mean age of GCA patients was 70 years (range: 63–79 years) and that
of TA patients 33.5 years. The mean disease duration was 1.3 years in
GCA and 4.9 years in TA patients. Two patients had not undergone GC
therapy at any point but were immediately treated with TCZ; five patients
were receiving a mean dosage of prednisone of 29.5 mg/day at the time of
the initial TCZ infusion. Substantial cardiovascular co-morbidity
(hypertension, peripheral occlusive arterial disease, coronary heart
disease) was found in six patients, hyperlipidaemia and diabetes in two
patients and osteoporosis secondary to longstanding GC therapy in
another two (table 1).
At baseline, before TCZ treatment, five patients presented with
constitutional symptoms such as fatigue and malaise, four with
polymyalgia, one with jaw claudication, one with amaurosis fugax, one
with visual impairment due to opticus neuropathy / anterior opticus
ischaemia, one with headache and hyperaesthesia of the scalp, one TA
patient with claudicatio of the arms and legs on exercise, and one TA
patient with para-aortal leakage of a composite graft placed after acute
dissection of the thoracic aorta and ischaemic abdominal pain six years
before (table 2). Three GCA and two TA patients exhibited active LVV on
MRA, including the thoracic and/or abdominal aorta and its branches. All
patients were followed up at the University Hospital of Bern for a mean
TCZ treatment period of 4.3 months (range 3–7 months). In six patients
initially presenting with constitutional and vasculitic symptoms, complete
remission was achieved within two months after the first TCZ infusion and remission was maintained despite continuous
and rapid reduction of systemic GC. The acute phase response (ESR and CRP serum levels) returned to normal in six out
of seven patients after the first TCZ infusion, and completely normalised in all patients after three months of treatment
(table 2). The five patients exhibiting active LVV on MRA before TCZ treatment showed no changes in vasculitic MRA
findings after one month, but improved on MRA follow-up after three months of TCZ treatment in the two TA patients
and entirely resolved in the three GCA patients. A representative follow-up MRA of GCA Patient 3 before and three
months after initiation of TCZ therapy is shown in figure 1. Continuous reduction of GCs over time was achieved in all
patients without any signs of clinical or laboratory relapse of LVV after the fourth TCZ infusion.
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After a mean follow-up of 8.3 months 3 GCA patients are still on monthly TCZ infusions and remain in complete
remission without GC comedication. In the other 2 GCA patients TCZ was stopped after 7 months due to remission and
without relapse. TCZ treatment had to be stopped in both TA patients after 4 and 8 months, in one patient because of
refusal of the health insurance company to further support the off label use of the biological drug, and in the other because
of disease relapse at a dose of 8 mg/kg and a 4-weekly interval. TA patients are currently treated with a combination of
GCs plus methotrexate and with GCs, methotrexate and infliximab (5 mg/kg at 4-weekly intervals) respectively.
We observed no adverse events. In two patients we recorded an increase in serum cholesterol levels which, however, did
not qualify for lipid lowering therapy.
Table 1: Patient demographic characteristics, co-morbidities and treatments.
Patient
Age/sex
Type of LVV Disease duration
(years)
Medication taken
prior to TCZ
GC dosage (mg/d)
with first TCZ infusion
Co-morbidities
1/63/M GCA, HP, MP 0.2 none 0 POAD, lipids↑
2/40/M TA, HP, MP 6 GCs 40 art. HT
3/73/M GCA, MP 0.3 none 0 art. HT, OP
4/71/F GCA, HP 0.8 GCs, MTX 20 art. HT, DM
5/79/F GCA, MP 4.5 GCs, MTX 10 art. HT, OP
6/64/F GCA, HP 0.5 GCs 27.5 art. HT, DM
7/27/F TA, MP 3.5 GCs, MTX, AZA, Infliximab 35 None
LVV = Large vessel vasculitis; GCA = Giant cell arteritis; TA = Takayasu’s arteritis, HP = Histologically proven; MP = magnetic resonance angiographically
proven; TCZ = Tocilizumab, POAD = Peripheral occlusive arterial disease; DM = Diabetes mellitus; OP = Osteoporosis; MTX = Methotrexate; AZA =
Azathioprine; GCs = Glucocorticoids; art. HT = arterial hypertension
Table 2: Outcome of three-month tocilizumab therapy in patients with large vessel vasculitis.
Patient “Malaise”
before/after TCZ
PMR
before/after
Claudicatio
before/after
ESR (mm/h)
before/after
CRP (mg/L)
before/after
GC dosis (mg/d)
before/after
1 ++ / none ++ / none POAD / nonea 91 / 2 56 / <3 0 / 0
2 none / none none / none abdomen / none 80 / 5 41 / <3 40 / 10
3 ++ / none ++ / none jaw / none 100 / 2 61 / <3 0 / 0
4 none / none none / none visualb / none 18 / 2 14 / <3 20 / 5
5 ++ / none +++ / none visualc / none 44 / 8 13 / <3 10 / 0
6 ++ / none ++ / none craniald / none 16 / 5 4 / <3 27.5 / 5
7 + / none none / none arms and legs / none 40 / <3 50 / <3 35 / 2.5
TCZ = Tocilizumab; PMR = Polymyalgia rheumatica; ESR = Erythrocyte sedimentation rate; CRP = C-reactive protein; POAD = Peripheral occlusive
arterial disease; + little (0–2 on a visual analog scale 1–10); ++ moderate (3–7 on a visual analog scale 1–10); +++ severe (8–10 on a visual analog scale
1–10); a resolved after catheter dilatation; b ischaemic opticus neuropathy; c amaurosis fugax; d headache and hyperaesthesia of the scalp.
Discussion
Collectively we documented a rapid and complete clinical remission of active GCA or TA by blockade of IL-6 using
TCZ. Importantly, blunting of the acute phase and disappearance of symptoms of inflammation preceded reduction and
resolution of the inflammation in the vessel wall, as demonstrated by MRA. This discrepancy is in line with published
data of RA patients [15]. In RA, suppression of CRP synthesis preceded reduction of synovitis by several months.
Whether this delay of local inflammation carries risks of vascular accidents needs to be determined in larger studies. In
our case series we fortunately did not note any side effects or complications.
The rapid remission allowed early reduction of daily GCs. As indicated, two patients were treated with TCZ only. In
summary, the seven cases strongly suggest that blockade of IL-6 might result in substantial reduction of cumulative GC
doses. This, in turn, has the potential to significantly reduce GC morbidity, a well defined burden in elderly people in
particular.
Three limitations have to be mentioned. First, the non-experimental study design, which does not allow efficacy to be
inferred in the absence of a control group; second, the small number of patients, and third, the short observation time.
Nevertheless, the fact that all patients responded to this IL-6 targeting strategy argues for interesting therapeutic potential,
not only for patients with newly diagnosed GCA but also for patients with relapse of the disease at moderate to high doses
of GCs. It remains to be analysed how long and with what infusion schedule of TCZ LVV should be treated. Based on the
reported follow-up findings some patients may maintain remission even after cessation of TCZ and GC medication, while
others may need shorter treatment intervals to stay in complete remission. A placebo-controlled prospective study will be
started shortly to analyse and compare short- and long-term effects of IL-6 blockade and to answer the question of dosage.
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